Compare RAPT & POET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAPT | POET |
|---|---|---|
| Founded | 2015 | 1972 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 498.4M | 550.2M |
| IPO Year | 2019 | N/A |
| Metric | RAPT | POET |
|---|---|---|
| Price | $35.10 | $6.79 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $57.00 | N/A |
| AVG Volume (30 Days) | 433.7K | ★ 8.2M |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $762,695.00 |
| Revenue This Year | N/A | $2,939.08 |
| Revenue Next Year | N/A | $710.17 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 535.87 |
| 52 Week Low | $5.67 | $3.09 |
| 52 Week High | $42.39 | $9.41 |
| Indicator | RAPT | POET |
|---|---|---|
| Relative Strength Index (RSI) | 56.26 | 56.04 |
| Support Level | $34.38 | $5.81 |
| Resistance Level | $36.92 | $7.90 |
| Average True Range (ATR) | 2.56 | 0.60 |
| MACD | -0.11 | 0.08 |
| Stochastic Oscillator | 50.37 | 47.25 |
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
POET Technologies Inc is a design and development company offering high-speed optical engines, light source products, and custom optical modules to the artificial intelligence systems market and hyperscale data centers. Its integration solutions are based on the POET Optical Interposer, a novel, patented platform that allows the seamless integration of electronic and photonic devices into a single chip using wafer-level semiconductor manufacturing techniques. POET's Optical Interposer platform also solves device integration challenges across a broad range of communication, computing, and sensing applications. The company operates geographically in the United States, Canada, Singapore and China.